Cormedix Inc (NAS:CRMD)
$ 5.18 -0.03 (-0.58%) Market Cap: 284.69 Mil Enterprise Value: 228.42 Mil PE Ratio: 0 PB Ratio: 4.89 GF Score: 54/100

CorMedix Inc at JMP Securities Life Sciences Conference Transcript

Jun 15, 2022 / 02:30PM GMT
Release Date Price: $2.88 (+4.35%)
Joe Todisco
CorMedix Inc. - CEO

Good afternoon, everybody. I am Joe Todisco; I'm the newly appointed CEO of CorMedix. I'm excited to be wrapping up my first month in seat.

I do believe that CorMedix is an attractive investment opportunity and that DefenCath, our lead product, will address a critical unmet medical need.

DefenCath is a catheter lock solution comprising heparin and taurolidine that we are developing for the reduction of catheter-related bloodstream infections. Our initial indication will focus on catheterized hemodialysis patients. But we do believe there will be broad applications across multiple therapeutic areas where catheters are utilized in patients.

Catheter-related bloodstream infections are a substantial burden in the US healthcare system, particularly in catheterized hemodialysis patients where the annual cost to the system in additional medical expenses is over $2.3 billion per year.

Between a quarter and a third of hemodialysis patients will have a CRBSI within the first 12 months of receiving hemodialysis via a catheter. The cost to treat

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot